Mobia Medical Inc.

05/13/2026 | Press release | Distributed by Public on 05/13/2026 17:59

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Presidio Management Group XII, L.L.C.
2. Issuer Name and Ticker or Trading Symbol
Mobia Medical, Inc. [MOBI]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O U.S. VENTURE PARTNERS, 1460 EL CAMINO REAL SUITE 100
3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026
(Street)
MENLO PARK, CA 94025
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/11/2026 C 1,906,809 A (1) 1,906,809 I See Footnote(2)(3)(4)
Common Stock 05/11/2026 C 96,772 A (1) 96,772 I See Footnote(3)(4)(5)
Common Stock 05/11/2026 C 1,309,155 A (1) 1,309,155 I See Footnote(3)(4)(6)
Common Stock 05/11/2026 C 314,090 A (7) 1,623,245 I See Footnote(3)(4)(6)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series E-2 Preferred Stock (1) 05/11/2026 C 5,610,776 (1) (1) Common Stock 1,610,903 (1) 0 I See Footnotes(2)(3)(4)
Series F Preferred Stock (1) 05/11/2026 C 1,030,642 (1) (1) Common Stock 295,906 (1) 0 I See Footnotes(2)(3)(4)
Series E-2 Preferred Stock (1) 05/11/2026 C 284,754 (1) (1) Common Stock 81,755 (1) 0 I See Footnotes(3)(4)(5)
Series F Preferred Stock (1) 05/11/2026 C 52,306 (1) (1) Common Stock 15,017 (1) 0 I See Footnotes(3)(4)(5)
Series F Preferred Stock (1) 05/11/2026 C 4,559,790 (1) (1) Common Stock 1,309,155 (1) 0 I See Footnotes(3)(4)(6)
Convertible Notes (7) 05/11/2026 C 3,769,090.08 (7) (7) Common Stock 314,090 (7) 0 I See Footnotes(3)(4)(8)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Presidio Management Group XII, L.L.C.
C/O U.S. VENTURE PARTNERS
1460 EL CAMINO REAL SUITE 100
MENLO PARK, CA 94025
X

Signatures

Dale Holladay, Authorized Signatory on behalf of Presidio Management Group XII, L.L.C 05/13/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Issuer's initial public offering (the "Offering") pursuant to its terms.
(2) These securities are held by U.S. Venture Partners XII, L.P. ("USVP XII").
(3) Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP.
(4) Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz are managing members of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner and a managing member of PMG XII and PMG SFI, respectively, and may be deemed to share voting and dispositive power over the reported securities held by USVP. Each such persons and entities disclaim beneficial ownership of the reported securities held by USVP, except to the extent of any pecuniary interest therein.
(5) These securities are held by USVP XII-A.
(6) These securities are held by USVP SFI, on its own behalf and as nominee for USVP SFI-A.
(7) The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Offering. The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
(8) Convertible Notes held by USVP SFI, on its own behalf and as nominee for USVP SFI-A.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Mobia Medical Inc. published this content on May 13, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 13, 2026 at 23:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]